Virtual Event | July 18, 2023

Process Development For A Diverse mAb Pipeline

Source: Cytiva

Our latest Bioprocess Online Live virtual panel event covered process development advances in a diversifying mAb market (i.e. bi- and tri-specific) with Amir R. Goudarzi, Sr. Director, Bioprocess Technologies at Bayer. During the discussion, they covered:·

  • Smart process development, including DoE, HTPD, and Mechanistic modeling
  • Keeping the "end in mind": Pre-clinical process development considerations for future successful manufacturing
  • Refining process economy
  • Critical quality attribute factors
  • Mistakes your peers have made, and how to avoid them

access the Virtual Event!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Cytiva